News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Extended cash runway with $33.3 million from at-the-market equity offerings in Q4’19 Focused and effective execution of clinical development of CUE-101 as a Phase 1 monotherapy dose escalation and expansion trial in HNSCC Immuno-STAT™ Platform for autoimmune disease featured in Merck presentation
View HTML
Toggle Summary Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC), which demonstrated tolerability and generated encouraging emerging metrics
View HTML
Toggle Summary Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights
CAMBRIDGE, Mass. , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical
View HTML
Toggle Summary Cue Biopharma Reports Second Quarter 2022 Financial Results
BOSTON , Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today second quarter 2022
View HTML
Toggle Summary Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
CAMBRIDGE, Mass. , Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, provided a business update for
View HTML
Toggle Summary Cue Biopharma Reports Third Quarter 2022 Financial Results
BOSTON , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today third quarter 2022
View HTML
Toggle Summary Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg cohorts, two have partial responses (1 confirmed and 1 unconfirmed) and two are manifesting reductions in target
View HTML
Toggle Summary Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee
Driscoll Brings More Than 20 Years of Experience in Financial Management of Life Sciences Companies CAMBRIDGE, Mass. , June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to
View HTML
Toggle Summary Cue Biopharma Strengthens Scientific and Clinical Advisory Board with Leading Oncology and Immunology Experts
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the appointment of three new key opinion leaders to its
View HTML
Toggle Summary Cue Biopharma to Host Business Update Call and Webcast
BOSTON , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will host
View HTML